Literature DB >> 17376485

The place of MRI in monitoring the individual MS patient.

Douglas L Arnold1.   

Abstract

Evidence of focal white matter inflammation on MRI can be related to relapses and chronic disability. The strength of the relationship depends on the stage of the disease. The predictive value is stronger early in the course of MS, when the focal white matter lesions are more important in the pathogenesis of MS. As the disease progresses, the predictive value of white matter lesions weakens and measures related to other, more diffuse aspects of the disease strengthen. Thus, lesion activity on MRI can be helpful as a guide to therapy, particularly early in the disease. Appropriate MRI criteria for a suboptimal response to therapy are not clear and may depend on the therapy being evaluated. The fact that diffuse pathology tends to progress despite effective suppression of focal inflammation is a cause for concern and needs to be addressed with new approaches to therapy that are more effective against this aspect of the disease.

Entities:  

Mesh:

Year:  2007        PMID: 17376485     DOI: 10.1016/j.jns.2006.11.023

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

Authors:  Giancarlo Comi; Stuart D Cook; Gavin Giovannoni; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony C Hamlett; Vissia Viglietta; Steven J Greenberg
Journal:  J Neurol       Date:  2012-12-21       Impact factor: 4.849

2.  Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Authors:  Douglas L Arnold; Elizabeth Fisher; Vesna V Brinar; Jeffrey A Cohen; Alasdair J Coles; Gavin Giovannoni; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Miroslav Stojanovic; Howard L Weiner; Stephen L Lake; David H Margolin; David R Thomas; Michael A Panzara; D Alastair S Compston
Journal:  Neurology       Date:  2016-09-02       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.